Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Rapid Micro Biosystems Inc(RPID)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RPID
09/24/2026: RPID (1-star) is currently NOT-A-BUY. Pass it for now.
Rapid Micro Biosystems is a commercial-stage company that provides automated microbial detection technology for the biopharmaceutical manufacturing industry. Its core strength lies in its proprietary Growth Direct platform, which offers a significant efficiency advantage over traditional, manual methods. The primary investment story centers on the scaling of its recurring revenue model as more facilities adopt this automated approach. However, the company faces significant execution and competition risks, including long sales cycles and pressure from well-resourced incumbents. This stock may suit growth-oriented investors with a high risk tolerance who are looking for exposure to digital transformation in biopharma, though they should monitor quarterly progress on system installations and cash management.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential in the digital transformation of biopharma, but scaling remains an execution challenge. |
| Momentum investor | Weak fit | The stock has struggled to maintain positive momentum, and this style is conditional on a clear, sustained upturn signal. |
| Value investor | Weak fit | As a loss-making, early-stage company, it does not currently meet traditional value investing criteria. |
| Dividend investor | Weak fit | Rapid Micro Biosystems does not pay a dividend and focuses on reinvesting cash for growth. |
| Low-risk investor | Weak fit | The company's financial profile, volatility, and early-stage status are generally unsuitable for low-risk investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock exhibits significant price fluctuations common in small-cap growth equities. |
| Valuation risk | Medium / high | Valuation is sensitive to long-term growth assumptions in a competitive, capital-intensive market. |
| Competition risk (Major life science firms) | High | Established competitors like Charles River and Thermo Fisher have deep market penetration and resources. |
| Business quality | Medium | While the technology solves a real problem, the business is still establishing its scale and profitability. |
| Dividend income | Low / none | Investors should not expect income from this growth-stage investment. |
| Execution risk | High | Success depends on the consistent, widespread adoption of the Growth Direct system by conservative pharmaceutical manufacturers. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -24.15% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.68M USD | Price to earnings Ratio - | 1Y Target Price 6.67 |
Price to earnings Ratio - | 1Y Target Price 6.67 | ||
Volume (30-day avg) 278.7K shares | Beta 1.44 | 52 Weeks Range 1.09 - 4.94 | Updated Date 09/24/2026 |
52 Weeks Range 1.09 - 4.94 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.08 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Equipment (Growth Direct System) | One-time sales of the automated microbial detection hardware platforms. | Revenue from the initial sale and installation of the testing robots. |
| Consumables and Services | Recurring sales of proprietary testing strips and recurring service maintenance contracts. | The reliable, recurring revenue part of the business that grows as more systems are used. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 60.89M | Price to Sales(TTM) 1.58 |
Enterprise Value 60.89M | Price to Sales(TTM) 1.58 | ||
Enterprise Value to Revenue 1.73 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 45.66M | Shares Floating 23.91M |
Shares Outstanding 45.66M | Shares Floating 23.91M | ||
Percent Insiders 10.11 | Percent Institutions 46.13 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Rapid Micro Biosystems Inc
Exchange NASDAQ | Headquarters Lexington, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President, COO & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 171 | Website https://www.rapidmicrobio.com |
Full time employees 171 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.